Patent ID: 7550433
Filing Date: 2009-06-23
Classification: A61K,A61P,B82Y,C07K

Abstract:
1. A method for treating a patient having a disorder characterized by a deficiency of erythropoietin or a low or defective red blood cell population, which method comprises administering once every 3 to 4 weeks to the patient a therapeutically effective amount of a compound that binds to and activates the erythropoietin receptor (EPO-R), wherein the therapeutically effective amount is a dosage of 0.025 to 0.5 milligram of the compound per 1 kilogram of body weight of the patient, wherein the compound comprises: (a) a first peptide monomer and a second peptide monomer, each of said first and second peptide monomers comprising the amino acid sequence (AcG)GLYACHMGPIT(1-nal)VCQPLR (SEQ ID NO: 14); (b) a linker moiety covalently bonding the first peptide monomer to the second peptide monomer; and (c) a spacer moiety covalently joining the linker moiety and a poly(ethylene glycol) (PEG) moiety, said PEG moiety comprising a linear, unbranched PEG having molecular weight of 10,000 to 60,000 Daltons.